undamentalytics Newsletter
Sign in

Gossamer Bio, Inc. key statistics and ratios

In fiscal 2025, Gossamer Bio, Inc. had an operating margin of -352.2% and a current ratio of 2.64. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Operating margin——−52.2%−352.2%−311.7%
Net margin——−49.3%−351.5%−235.0%
Free-cash-flow margin——−3.0%−353.5%−305.2%
Return on equity——−122.5%——
Return on assets−84.2%−61.5%−18.0%−69.9%−100.5%
Asset turnover——0.370.200.43
Current ratio5.325.946.882.640.53
Debt to equity195.4%19.8%0.0%——
Interest cover (operating income ÷ interest)n/mn/mn/mn/mn/m
R&D as % of revenue——120.7%359.2%307.7%
Capital spending as % of revenue——0.0%0.2%0.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $77m
Short-term assets $73mLonger-term assets $4m
What it owes, and who funded it · $171m
Short-term liabilities $138mLonger-term liabilities $33mShareholders' equity $-94m
  • Short-term assets cover short-term liabilities $73m of assets due within a year against $138m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $73m short-term assets against $33m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$166m against $11m of interest.

From Gossamer Bio, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: GOSS vs SIGAGOSS vs TNGXGOSS vs OCULGOSS vs NKTR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Gossamer Bio, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gossamer Bio, Inc.